(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 6 October 2005 (06.10.2005)

(10) International Publication Number WO 2005/092863 A1

- (51) International Patent Classification7: C07D 231/38. 403/04, 409/04, 405/12, 403/12, 403/10, A61K 31/415. A61P 31/12
- (21) International Application Number:

PCT/GB2005/001071

- (22) International Filing Date: 22 March 2005 (22.03.2005)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0406916.7 26 March 2004 (26,03,2004) GB 0406918.3 26 March 2004 (26,03,2004) GB 0423000.9 15 October 2004 (15.10.2004) GB 0423001.7 15 October 2004 (15.10.2004) GB

- (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BRAVI, Gianpaolo [IT/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SGI 2NY (GB). CORFIELD, John, Andrew [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). GRIMES, Richard, Martin [GB/GB]; GlaxoSmithKline. Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY

(GB). GUIDETTI, Rossella [IT/GB]; c/o GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). LOVEGROVE, Victoria, Lucy, Relen [GB/GB]; c/o GlaxoSmithKline, Gunnels Wood Road. Stevenuge Hertfordshire SG1 2NY (GB). MORDAUNT, Jacqueline, Elizabeth [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). SHAH, Pritom [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). SLATER, Martin, John [GB/GB]; GlaxoSmithKline. Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

- (74) Agent: BAKER, Suzanne, June: GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM. AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, YD, YL, YN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN. MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW. MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: 4-CARBOX PYRAZOLE DERIVATES USEFULAS ANTI-VIRAL AGENTS

$$R^{2}$$
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{3}
 R^{4}
 R^{4}

2005/092863 A1 (57) Abstract: Novel antiviral compounds of Formula (I): wherein: A represents hydroxy; R1 represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, C1-6alkyl or -C5-9cycloalkyl, each of which may be optionally substituted; R2 represents substituted phenyl, or -(CH2)nC5-7cycloalkyl optionally substituted on the cycloalkyl; R3 represents heterocyclyl or heteroaryl; optionally substituted phenyl or optionally substituted -C1-falkyl; R4 represents hydrogen; and salts, solvates and esters thereof, processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.